CholinergicClinical dose · 300–600mg/day (the positive Alzheimer's trial used 1200mg/day)Onset · Acute effects at 60 minutes in one RCT; the Alzheimer's trial measured benefit at 90 and 180 days

Alpha-GPC

Name: Alpha-GPC — Human Clinical Effect Matrix
Creator: The Nootropic Lab
License: https://creativecommons.org/licenses/by/4.0/

A multicenter RCT in mild-to-moderate Alzheimer's dementia (De Jesus Moreno, 2003, n=261) found 1200mg/day improved ADAS-Cog, MMSE and global scores versus placebo at 90 and 180 days, and a 2023 meta-analysis supports benefit in cerebrovascular cognitive impairment. In healthy men, a single 315–630mg dose improved Stroop performance but not N-Back or Flanker (Kerksick 2024). Sports trials are inconsistent: a lower-body force gain after 6 days at 600mg (Bellar 2015), no strength effect at 250–500mg for 7 days, and no power-output effect after a single 630mg dose.

By The Nootropic Lab editorial teamUpdated Oct 9, 20268 min read✓ Fact-checked

Evidence reviewed: Sep 28, 2026

Mechanism of action

Alpha-GPC (alpha-glycerylphosphorylcholine) is the most bioavailable choline precursor. It delivers choline directly across the blood-brain barrier, where it is used to synthesise acetylcholine. It also supports cell membrane phospholipid synthesis. It is often marketed for growth hormone release, but a 2024 RCT at 630mg found no growth hormone difference versus placebo.

Clinical evidence summary

Human effect matrix

Based on human clinical trials only. Animal and in-vitro data excluded.

Effect	Evidence	Magnitude	Studies	Notes
Acetylcholine Synthesis	strong	Large	2	Plasma choline rose faster and higher than with citicoline in a 1992 study — but that used intramuscular injection, so oral onset is not directly measured. A 2024 RCT found cognitive effects 60 minutes after an oral dose.
Memory & Cognition	moderate	Moderate	2	Strong evidence only in Alzheimer's patients at 1200mg/day. In healthy men at 630mg, Stroop improved but N-Back (working memory) and Flanker did not.
Athletic Power Output	mixed	Small	3	Lower-body force gain after 6 days at 600mg; no strength effect at 250–500mg over 7 days (only a jump-velocity effect at 250mg); no power-output effect after a single 630mg pre-exercise dose.
Neuroprotection	moderate	Moderate	2	Cognitive and functional benefit in Alzheimer's and cerebrovascular dementia populations; not tested for healthy brain ageing.

Evidence key: Strong = multiple consistent RCTs · Moderate = smaller/fewer RCTs · Preliminary = early trials or small n · Mixed = conflicting results

Documented benefits

Cognition in Alzheimer's and cerebrovascular dementia (1200mg/day)
Acute Stroop (executive) performance in healthy men
Raises plasma choline

Side effects & cautions

Well tolerated
Headache if combined with other cholinergics
500mg/day significantly suppressed serum TSH (thyroid-stimulating hormone) in a 7-day trial

How to take

Dosage300–600mg/day — matches the healthy-adult and sports trials; the strongest (Alzheimer's) evidence used 1200mg/day

TimingMorning or 30–60 minutes before a demanding cognitive task or workout

With foodCan be taken with or without food. Slightly better absorbed with a small meal. Do not take late in the day — the acetylcholine activation can interfere with sleep.

FormsCapsule (common), powder. Alpha-GPC is hygroscopic (absorbs moisture from air) — powder can become sticky; capsule form is more practical. 50% and 85% concentration forms exist; the 50% form (more common) doubles the serving size but is equivalent in active dose.

Stacking recommendations

Ingredients that pair well with Alpha-GPC and why.

Lion's Mane

Alpha-GPC provides immediate acetylcholine support; Lion's Mane drives long-term NGF synthesis. Neither overlaps mechanistically — a clean acute + long-term pairing.

Bacopa Monnieri

Alpha-GPC handles acute memory encoding via acetylcholine; Bacopa handles memory consolidation and storage. Together they cover both encoding and consolidation stages of memory formation.

Huperzine A

Huperzine A prevents acetylcholine breakdown while Alpha-GPC increases acetylcholine synthesis. Powerful combination in theory — but use with caution and low doses, as cholinergic overload (nausea, headache, muscle cramps) is a real risk. Not recommended without experience.

Frequently asked questions

Alpha-GPC vs Citicoline — which is better for focus?

Both are excellent. Alpha-GPC has a slight edge for acute cholinergic effects and is preferred for workout performance. Citicoline also provides cytidine (uridine precursor), giving it a broader neuroprotective profile. For pure focus and acetylcholine, Alpha-GPC wins slightly; for comprehensive brain health support, Citicoline is more complete. Don't stack them together — you'll get too much choline activity.

Is it safe to combine Alpha-GPC with Huperzine A?

Use caution. Both increase acetylcholine (Alpha-GPC via synthesis, Huperzine A via inhibiting breakdown). The combination is potent and can cause cholinergic overstimulation — symptoms include nausea, headache, excessive salivation, and muscle cramps. If combining, use lower doses of each (e.g. 200mg Alpha-GPC + 50mcg Huperzine A) and do not take daily.

Why does Alpha-GPC powder go sticky?

Alpha-GPC is highly hygroscopic — it absorbs water from the air quickly. This is normal and doesn't affect potency. Store in an airtight container in a cool, dry place. Capsule form avoids this problem entirely.

Is there a cardiovascular risk with Alpha-GPC?

Unresolved. The CARDIA cohort study (published 2024) linked higher plasma choline — not alpha-GPC supplements — with incident cardiovascular disease, while a meta-analysis of dietary choline intake found no association. No study has tested alpha-GPC supplementation directly for cardiovascular outcomes. If you have cardiovascular disease, discuss it with your doctor.

Alpha-GPC in the EU

Alpha-GPC is moving through the EU's novel food process. An application covering L-alpha-GPC derived from soya phospholipids has a public dossier summary published by the European Commission in its ongoing-applications series (file 2023-12770), and EFSA published a favourable safety opinion in 2026 finding no safety concerns under the proposed conditions of use. A scientific safety opinion is a separate step from the Commission's formal authorisation, which is what adds a novel food to the Union list and determines whether and how it may be placed on the EU market.

Safety Opinion Issued, Authorisation Still Pending

EFSA's 2026 opinion on L-alpha-GPC from soya phospholipids as a novel food concluded favourably on safety, stating "the Panel concludes that the NF does not raise safety concerns under the proposed conditions of use." This opinion responds to a novel food application submitted under Regulation (EU) 2015/2283, and the Commission's public dossier summary for that application is filed under ongoing applications. Under Article 6(2) of the Regulation, "only novel foods authorised and included in the Union list may be placed on the market," so the Commission's authorisation step, not the EFSA opinion, is what governs sale.

Products in the EU

None of the stacks we have audited are listed in our catalogue in the EU yet.

EU food supplement (Reg. 1924/2006 claims)

Is alpha-GPC officially approved as a novel food ingredient in the EU?

The EU treats these as separate steps. EFSA has issued a favourable safety opinion, and the Commission's published dossier summary for the L-alpha-GPC application sits in its ongoing-applications series. Market authorisation requires a Commission act adding the ingredient to the Union list of authorised novel foods; check the current Union list for the up-to-date status.

Did EFSA find safety concerns with alpha-GPC?

No. EFSA's 2026 scientific opinion concluded that the novel food "does not raise safety concerns under the proposed conditions of use." A favourable safety opinion is a necessary step toward authorisation, but it is not itself the market authorisation.

EU country guides

Sources: EFSA Journal 2026;24(5):e10008 — Safety of L-alpha-glycerylphosphorylcholine (L-alpha-GPC) from soya phospholipids as a novel food · European Commission public summary of the ongoing novel food dossier for L-alpha-GPC from soya phospholipids (lecithin) · Regulation (EU) 2015/2283, Article 6(2) -- only authorised novel foods may be marketed

Regulatory note

Cognitive-effect language on this page describes ingredient mechanisms studied in clinical trials. Health claims on supplements sold in the EU are governed by Regulation (EC) No 1924/2006; only European Food Safety Authority (EFSA) approved claims may appear on product labelling. This page is editorial, not promotional, and does not constitute medical advice. Consult a qualified healthcare professional before starting any supplement.

Sources (7)expand

← Back to Ingredients Guide